DividendMapper
Bruker Corporation logo

BRKR

Bruker Corporation

  • Healthcare
  • US companies in Healthcare (47)
  • NASDAQ · USD
  • Mkt cap $9.3bn

$60.74

as of 27 Oct 2026, 9% below its 52-week high

Screens as reasonably placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield
0.33%Last 12 months of regular payments at today's price
Forward yield
0.33%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover
Not availableEarnings over dividends paid
Cash cover
2.9×Free cash flow over dividends paid
5y dividend growth
+4.6% a yearNo cut since FY2017
Next ex-dividend date
Estimated8 Dec 2026Quarterly dividend of about $0.05

Compared with US companies in Healthcare (47)

  • Trailing yield is lower than 40 of the 46 other US companies in Healthcare.
  • 5y dividend growth (as paid) is lower than 28 of the 38 other US companies in Healthcare with a 5y growth figure.

Quality

56

Moderate

Capacity to keep growing the dividend

Risk

40

Low

Signals of dividend-cut pressure

Trim

52

Moderate

How extended the valuation looks

Why Quality is 56

BRKR against US companies in Healthcare (47)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of BRKR’s past readings.

  • Yield0.33%P43, neutral for this measure
  • FCF payout58.3%P91, poor for this measure
  • Net debt / EBITDA6.99P100, poor for this measure
  • DGR 5y+4.6%P45, neutral for this measure
  • ROIC1.0%P0, poor for this measure
Open valuation history

Forecast your income with the BRKR dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.